Drugs‎ > ‎

Citalopram

Class
  • Furancarbonitrile SSRI
Indications
Administration/Absorption
  • Oral
  • Single daily dose
  • Bioavailability is 80% following oral administration
Dosage

Distribution
  • Volume of distribution 12 L/kg
Mechanism
  • The antidepressant, antiobsessive-compulsive, and antibulimic actions of Citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin
  • Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors
  • Has only very weak effects on norepinephrine and dopamine neuronal reuptake
  • Has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors
    • Antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs
  • Citalopram does not inhibit monoamine oxidase.
Excretion
  • Half-life 35 hrs
  • The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance
  • Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative
Side effects
Interactions

Contraindications

Comments